Intco Medical Technology Stock: Balance Sheet and Debt
300677.SZIntco Medical Technology has a debt to equity ratio of 0.95 and an interest coverage of 4.3x. Since the end of 2025 debt has exceeded cash, at the end of 2024 it was the other way round.
Daily figure as of 20 Nov 2026
Balance Sheet Over Time
At the end of 2024 cash still exceeded debt by $887.77M. Interest coverage fell from over 100x in 2020 to 4.3x.
Total Assets and Equity Ratio
How large the balance sheet of Intco Medical Technology Co., Ltd. is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2013 | $105.67M | $2.4M | not split out | 21.0% | $24.92M |
| 2014 | $98.48M | $2.85M | not split out | 25.6% | $27.47M |
| 2015 | $113.12M | $3.2M | not split out | 55.1% | $13.82M |
| 2016 | $174.56M | $4.84M | not split out | 46.0% | $38.13M |
| 2017 | $248.74M | $4.81M | not split out | 65.6% | −$9.39M |
| 2018 | $363.69M | $13.74M | not split out | 52.5% | −$6.27M |
| 2019 | $448.8M | $29.3M | not split out | 50.2% | $18.9M |
| 2020 | $1.94B | $52.42M | not split out | 73.0% | −$920.72M |
| 2021 | $3.09B | $94.49M | not split out | 78.2% | −$1.2B |
| 2022 | $3.22B | $87.52M | not split out | 74.7% | −$766.46M |
| 2023 | $4.06B | $85.03M | not split out | 60.2% | −$802.06M |
| 2024 | $5.19B | $115.05M | not split out | 51.1% | −$887.77M |
| 2025 | $6.01B | $109.37M | not split out | 46.3% | $656.91M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.
Equity and Debt
What the Company Owns and Owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2013 | $7.92M | $21.92M | $32.84M | 1.48 |
| 2014 | $15.56M | $25.26M | $43.03M | 1.7 |
| 2015 | $9.25M | $62.28M | $23.07M | 0.37 |
| 2016 | $15.88M | $80.32M | $54.01M | 0.67 |
| 2017 | $47.03M | $163.13M | $37.64M | 0.23 |
| 2018 | $128.69M | $190.96M | $122.42M | 0.64 |
| 2019 | $130.83M | $221.6M | $149.73M | 0.66 |
| 2020 | $958.56M | $1.4B | $37.84M | 0.03 |
| 2021 | $1.24B | $2.38B | $38.27M | 0.02 |
| 2022 | $998.57M | $2.37B | $232.11M | 0.1 |
| 2023 | $1.87B | $2.4B | $1.07B | 0.44 |
| 2024 | $2.81B | $2.61B | $1.92B | 0.73 |
| 2025 | $1.98B | $2.74B | $2.64B | 0.95 |
Debt to equity divides debt by total equity, including non-controlling interests, as S&P calculates it. The equity column shows the part that belongs to shareholders.
Debt of Industry Peers
Intco Medical Technology's debt to equity is higher than that of 80 of 81 other stocks in the Healthcare sector.
| Stock | Debt to equity | Equity ratio |
|---|---|---|
| Asahi Intecc | 0.05 | 79.9% |
| Teleflex | 0.87 | 45.0% |
| Gan & Lee Pharmaceuticals. | 0.01 | 92.1% |
| Merit Medical Systems | 0.57 | 59.0% |
| Intco Medical Technology | 0.95 | 46.3% |
| ICU Medical | 0.66 | 52.4% |
| Stevanato Group | 0.32 | 58.4% |
| Envista Holdings | 0.51 | 54.7% |
| SCHOTT Pharma | 0.09 | 54.5% |
Figures from the latest fiscal year. The eight peers closest in market value, largest first.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
